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Abstract 
Many important analgesics relieve pain by binding to the µ-Opioid Receptor (µOR), which makes 
the µOR among the most clinically relevant proteins of the G Protein Coupled Receptor (GPCR) 
family. Despite previous studies on the activation pathways of the GPCRs, the mechanism of 
opiate binding and the selectivity of µOR are largely unknown. We performed extensive molecular 
dynamics (MD) simulation and analysis to find the selective allosteric binding sites of the µOR 
and the path opiates take to bind to the orthosteric site. In this study, we predicted that the allosteric 
site is responsible for the attraction and selection of opiates. Using Markov state models and 
machine learning, we traced the pathway of opiates in binding to the orthosteric site, the main 
binding pocket. Our results have important implications in designing novel analgesics. 
Introduction 
The most powerful analgesic and addictive properties of opiates are mediated by the µ-Opioid 
Receptor (µOR).1, 2 Since this receptor is primarily responsible for the effects of opium, the µOR 
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is one of the oldest drug targets for the discovery of analgesics.3 µOR activation results in signaling 
through the heterotrimeric G protein Gi, resulting in analgesia and sedation. Activity studies of 
µOR have revealed that subtle changes in ligand structure can make the difference between an 
agonist and an antagonist, so there is a general philosophy within the GPCR drug community that 
distinct pharmacophores are responsible for efficacy (message) or selectivity (address).4, 5 An 
efficient opioid (medicinally perfect) would relieve pain potently without side effects such as 
harmful respiratory effects or constipation, show sustained efficacy in chronic treatments, and not 
cause addiction.6, 7 Design of such an ideal opioid requires a fundamental and deep understanding 
of drug binding, dynamics, and receptor activation mechanism.8, 9 10 
In spite of significant studies in the past few years on the conformational changes triggered due to 
drug binding,11 the origin of the selectivity of certain receptors to specific drugs is largely 
unknown.9, 12-14 Does this selectivity originate from the binding pocket or are there other significant 
selectivity sites that prescreen the drug? Following this line of thought, it is important to answer 
the question regarding the binding dynamics, as well as the path that the drug travels from the 
extracellular environment to the binding pocket. It is still unknown how drugs diffuse through a 
highly tortuous cavity to arrive at the binding pocket, also called the orthosteric site. 
To address the above questions, we used molecular dynamics (MD) simulations with the state of 
the art post-processing software MSMBuilder15 and machine learning (ML) algorithm Time-
Structure Based Independent Component Analysis (tICA).16,17 First, we found an allosteric site 
responsible for the selectivity of µOR through monitoring the binding ability of different ligands. 
Second, we tried to understand the pathway of a ligand from the allosteric site (selectivity site) to 
the orthosteric site (main binding pocket). Since ligands need to assume specific and rare 
orientations to permeate through the tortuous and high-energy barrier cavity of the receptor, 
conventional long-trajectory MD simulations, with continuous trajectory lengths up to 2 µs, 
starting from allosteric site usually cannot show the full binding pathway; therefore, using Markov 
state models (MSMs) and tICA would be beneficial to unravel the binding dynamics. The 
identifications of the screening mechanism of µOR and the permeation dynamics of opiates have 
important implications in designing analgesics because they need to have a specific fingerprint and 
molecular architecture to be recognized by the allosteric screening.  
Methods 
We performed MD simulations with NAMD 2.18  A typical simulation set up consisted of the 
receptor (inactive structure, PDB code: 4DKL), lipid bilayer, water, and ions (~98000 atoms; 
Supporting Information Figure S1).	 The protein structure was then aligned to its predicted 
membrane pose based on its entry in the Orientations of Proteins in Membranes Database.19 A 
lipid bilayer (POPC) membrane was created (90 Å × 90 Å) using Visual Molecular Dynamics 
software.18 Subsequently, the protein was inserted in the membrane  and 4 ligands of the same type 
were placed randomly on the extracellular section of the membrane. For each ligand in (BU72, 
morphine, oxymorphone, IBNtxA, and carazolol), a set of 25 simulations were created (see 
Supporting Information, Figure S1). After placing the ligands in the simulation box, the entire 
system, including the receptor, membrane, and ligands, was solvated by a 25 Å thick slab of water 
on each side of membrane. We ran the simulation for 40 ns to equilibrate the system of lipid bilayer 
and protein. The ionic concentration of NaCl was 0.15 M. We used the CHARMM36 force field 
parameters for the protein, TIP3P water molecules, and ions. We parametrized the ligands using 
Forcefield Toolkit (FFTK).20 All quantum mechanical (QM) calculations were carried out in the 
Gaussian software.21 First, we optimized the geometry of the ligand and then computed the partial 
charges in presence of water to account for the solvent-ligand dipole effect. We broke the molecule 
into three parts for the torsion scan because electronic structure calculation for a ligand with 49-
58 atoms is computationally expensive. We scanned the torsion angles with 5˚ iterations. The 
MP2/6-31 G* level of theory and basis set is used for parametrization, optimization, charge 
calculation, and torsion scan. The SHAKE algorithm was used to maintain the rigidity of the water 
molecules. Periodic boundary conditions were applied in all three directions. The cutoff distance 
for the Lennard-Jones (LJ) interactions was 15 Å. The long-range electrostatic interactions were 
computed using the Particle-Mesh-Ewald (PME) method. The time step was selected to be 2 fs. 
For each simulation, energy minimization was performed for 100,000 steps. The system was then 
equilibrated for 5 ns in the NPT ensemble at 1 atm pressure and 300 K temperature. NPT 
simulation ensures that the water concentration is equal to the bulk value of 1 g/cm3. Temperature 
was maintained at 300 K by applying the Nosè-Hoover thermostat with a time constant of 0.1 ps. 
In total, 125 simulations were run, each of length 500 ns, producing an aggregate trajectory length 
of 72.5 µs for the allosteric affinity simulation data set. 
The second set of simulations were performed to find the pathway between the allosteric and 
orthosteric sites. We do not have prior knowledge of the pathway, but we know the possible 
allosteric sites and the definite orthosteric pocket. While all the hypothetical paths from the 
allosteric site to the orthosteric site are spatially short and traverse a sterically constricted region, 
it is possible to generate different ligand orientations and positions along these hypothetical paths. 
We generated 420 orientations/positions between the allosteric and orthosteric sites. The algorithm 
for generation of different orientations/positions is as follows: 1. Starting from the allosteric site, 
rotate the ligand about x, y, and z axes, every 15˚. 2. Move the ligand closer to orthosteric site by 
1 Å each iteration and repeat step 1. Using this algorithm, we were able to account for many 
possible initial configurations of the ligand along the path.   
Analysis was driven by the Conformation software package,22 a custom Python code for analysis 
of MD simulations, that leverages MSMBuilder23 and MDTraj.24 The package was modified 
specifically to incorporate ligand-protein interaction features, in this case for a large GPCR MD 
dataset. All residue-ligand pairs within 6.6 Å measured by closest heavy atom distance in either 
crystal structure were selected. Then, for each of these approximate residue-ligand pairs, both the 
closest heavy atom distance and Cα distance were computed for each frame in each trajectory. 
Next, the Sparse tICA algorithm was applied to determine the reaction coordinates, or slowest 
collective degrees of freedom (up to the ten slowest in this case), of the protein and ligand. A k-
means model was trained with k=1,000 clusters. Finally, an MSM was constructed with lag time 
25 ns and prior counts 1x10-5. The equilibrium state probabilities from the MSMs were used 
individually in each condition to generate the free energy surfaces projected onto the features and 
tICA coordinates (tICs). 
 
Results and Discussion 
1. Characterization of the Key Motifs in attracting Drug from Solvent to the Receptor  
In the first set of simulations, we ran simulations for all the ligands (BU72, morphine, 
oxymorphone, IBNtxA, carazolol) to identify the allosteric site and the average time it takes for 
the ligands to stably bind to the allosteric site (we call this “time to bind”). We set the root-mean-
square deviation (RMSD) and binding time criteria to <7.5 Å and >100 ns, respectively, and 
checked that the binding was within 5 Å of the extracellular lumen of µOR. The RMSD criteria of 
7.5 Å was selected because the average RMSD of BU72 in all binding events is 7.43 Å. As 
mentioned in the method section, we performed 25 simulations for finding the allosteric binding 
sites of BU72 and other ligands and the 7.5 Å criteria is the average RMSD of BU72 center of 
mass (COM) while bound to allosteric site. (see the supporting binding movie). The histogram plot 
of time to bind for BU72 shows the lowest time to bind among all the tested molecules (Figures 
1a, 1b, 1c, and 1d). Among 25 simulations for IBNtxA, only one binding event is observed (Figure 
1d). It has been shown that IBNtxA has a high affinity to bind 6 transmembrane (6TM) splice 
variant µOR but significantly less so to the 7TM splice variant25 and this agrees with our results 
(Figure 1d). We also simulated carazolol as a control to see if the allosteric site of µOR can bind 
to non-opioid ligands. Carazolol is a high affinity antagonist to the β-adrenergic receptor.26 In 25 
binding simulations with carazolol, we did not observe any binding to the µOR (Figure 1d). The 
order of binding events out of 25 samples for opioids is: BU72>oxymorphone>morphine>IBNtxA 
(Figure 1e). To compare the motion characteristics of ligand in solvent, allosteric, orthosteric 
inactive (PDB: 4DKL), and orthosteric active (PDB: 5CML), we computed the RMSD of BU72 
in each case (Figure 1f). The average RMSDs of BU72 are 33.35 Å, 7.43 Å, 3.44 Å, and 2.12 Å 
in solvent, allosteric site, orthosteric (inactive), and orthosteric (active), respectively. The RMSD 
is computed for the COM of BU72 with respect to aligned µOR. The ligand’s RMSD decreases 
gradually from solvent to allosteric site and then to the main binding pocket. 
We also looked at the hydration of ligand during its binding, from solvent to the allosteric site 
(Figure 2a). We counted the waters within 5 Å of BU72 in each frame of the simulation. On 
average, ∼40 water molecules encapsulated BU72 when it was in the bulk solvent. Upon binding, 
BU72 dehydrated and lost half of its water (in the allosteric site, BU72 was accompanied by ~20 
water molecules); compared to when it was in the orthosteric (active) site, BU72 had four times 
more water molecules (Figure 2a). The higher hydration level of BU72 in the allosteric site was 
due to its exposure to the solvent in the extracellular part of the µOR. 
The schematics and detailed interaction maps of BU72 in the allosteric and orthosteric sites are 
depicted in Figure 2b and Figure 2c. Figure 2b shows a completely different orientation of BU72 
in the allosteric and orthosteric sites. There is a 17.86 Å of distance between the COM of BU72 in 
allosteric site and orthosteric site. Initially and before the stable binding of BU72 to allosteric 
binding site, the ligand is captured by certain motifs in the extracellular upper loop residues 
(GLU3101.93, GLN2122.60). The allosteric site is composed of residue groups (GLU3101.93, 
PHE3137.30, GLN3147.31, THR3157.32, THR3117.28), (ARG2119.54, GLN2128.88, SER2149.40, 
ASP2162.87, THR218ECL2), and (ASN1272.63, TYR1282.64, MET1302.66, GLY131ECL1), which are 
shown in Figure 2c.  
2. Machine Learning Revealed the Pathway from Allosteric Site to Orthosteric Site 
In long time trajectories of nearly 1 µs, we did not observe an event of allosteric to orthosteric 
transition of BU72. This implies that the transition timescale from the allosteric site to the 
orthosteric site may not be tractable with unbiased MD simulation alone. To characterize the 
transition pathway of the ligand from the allosteric site to the orthosteric site with an unknown 
timescale, we used an unsupervised machine learning algorithm – Sparse tICA27 – in conjunction 
with MSMs.15, 28, 29 tICA analyzes large datasets of trajectories in an unbiased way to find the 
slowest reaction coordinates sampled by the system.16 Since such reaction coordinates are defined 
by linear combinations of features, the choice of featurization played a key role in this analysis. 
Custom code was written and incorporated into the open source MDTraj24 package that automates 
the measurement of pairwise distances between individual heavy atoms on simulated ligands and 
protein residues with which it might interact. In addition to its role in interpretation, tICA also 
served as a dimensionality reduction technique for discretizing the protein into conformational 
states (k-means) that were then used to construct an MSM. The MSM of binding, which we include 
in the Supporting Information, enables biophysicists and medicinal chemists alike to query a 
compendium of partial trajectories that link the allosteric and orthosteric binding pockets of µOR. 
The free energy landscape of orientation-position of BU72 shows a convoluted path between 
allosteric and orthosteric sites (Figure 3). The aggregate MD data is projected onto x and y-axes, 
tIC1 and tIC2, the first and second slowest degree of freedom, respectively, accessible to the ligand 
in simulation. While tIC1 represents the distance between allosteric and orthosteric sites, tIC2 
represents the orientation of BU72 with respect to the protein aligned structure. The two valleys 
next to each other (at approximate positions (0.5, -0.5), (1.3, -1.1) in arbitrary units) are the 
allosteric sites from which BU72 starts to travel to the orthosteric site with the coordinates of (-
0.2, -1) in Figure 3. Another metastable well is observed at (1.0, 2.0) which has the characteristic 
of the initial drug hooking site. The highest energetic barrier on the path is located at (-0.1,0.8). 
The features (residues) that were involved in the hooking site and allosteric site are elaborated on 
Figure 2c and 2d.  
Using transition path theory (TPT),30, 31 we determined some of the most probable paths from 
allosteric to orthosteric sites (Figure 3). These paths originated from allosteric site 1 or site 2 to 
the orthosteric site and passed through the high-energy barriers on the free energy landscape. The 
network map of the connections between MSM clusters shows multiple possible paths connecting 
the orthosteric site to the allosteric sites (Figure 4). Between the two allosteric sites, site 2 is more 
populated than site 1 (Figure 4). Some of the paths (see Supporting Information for the paths’ 
cluster numbers) suggest that BU72 starts at site 1, traverses through site 2, and then reaches the 
orthosteric site. The orientation of BU72 shows the rotation of the phenolic hydroxyl group toward 
the receptor’s cytosol (Figure 5a).  Snapshots taken from the MSM states on the paths show that 
the N-methyl group of BU72 gradually becomes perpendicular to membrane plane (Figure 5b). 
Initially and at allosteric sites, the BU72 N-methyl is almost parallel to the membrane plane (Figure 
5b). We also characterized the pose and the neighboring residues to BU72 at the highest energy 
clusters on the free energy plot (Figure 5c). We observed the bond stretch (on an average, 0.8 Å) 
between phenyl group and BU72 at this state (high-energy barrier state, Figure 5c), which we 
attribute to the strong cavity confinement. The unusual crystallographic state of BU72 was 
observed in the ref.5 The important residues that were within 5 Å of BU72 and were selected by 
tICA are shown in Figure 5c. The residues in highly constricted path are LEU21945.52, TRP3187.35, 
ILE2966.51, ILE3227.38, ASP1473.32, TYR1463.33, TYR3267.43, and TRP2936.48  (Figure 5c).  
Conclusions 
In summary, we identified the fingerprint that defines the selectivity motif of µOR and is 
responsible for screening the drug and accepting the opiate scaffold. This motif is comprised of 
amino acids that are perched on top of the extracellular part of the receptor. We also showed the 
existence of allosteric sites that are responsible for stabilizing the ligand binding to the receptor 
and guiding the ligand to the main binding pocket at the orthosteric site. The allosteric sites of 
µOR are only selective to opioids. The path from allosteric to orthosteric site is a tortuous path 
with high-energy barriers. Using ML and MSMs, we mapped the free energy landscape of a ligand 
traversing from the allosteric site to the orthosteric site. We characterized the ligand’s pose at 
different states along the path and demonstrated the rotation of the N-methyl group toward the 
polar cavity of the orthosteric site.  
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Figure 1: a| Binding time distribution from solvent to allosteric site of inactive µOR for BU72. b| Binding time from 
solvent to allosteric site of inactive µOR for morphine. c| Binding time from solvent to allosteric site of inactive µOR 
for oxymorphone. d| Binding time from solvent to allosteric site of inactive µOR for both IBNtxA and carazolol. e| 
Number of binding events to allosteric sites out of 25 simulations. f| Comparison of ligand RMSD in different locations 
with respect to the receptor. 	
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Figure 2: a| Comparison of BU72 hydration in solvent and in an allosteric site with hydration in the orthosteric site 
of µOR.  b| Schematic comparison of the allosteric and orthosteric sites and the respective orientation and the distance 
between two sites. c| The residues involved in the initial “hooking mechanism” of the ligand. d| Allosteric binding 
pocket residues, the selectivity filter, and relative orientation of BU72 in the allosteric binding pocket.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: a| Free energy landscape of BU72 travelling for two allosteric sites to the orthosteric site. The x-axis 
represents the distance between the orthosteric and allosteric sites. The y-axis represents the ligand orientation with 
respect to fixed protein structure. The orange, light blue, blue, and red lines on the plot represent the most probable 
paths originated from TPT.  
 Figure 4: Network view of the BU72- µOR MSM states depicting allosteric-orthosteric transition. Each node is an 
MSM state and labeled based on the cluster number. The edges (connecting lines) are possible transition paths. The 
larger nodes represent more populated MSM clusters.  The colors are set based on the proximity to the orthosteric site 
(the darker, the closer).  
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Figure 5: a| Respective position and orientation of BU72 in allosteric and orthosteric sites of µOR. b| Multiple 
snapshots of BU72 obtained from MSM clusters on the path from allosteric to orthosteric sites. Each color represents 
different cluster states (in our MSM model, the clusters are [47, 93, 48, 9, 43] plus the allosteric and orthosteric initial 
seed poses. c| Snapshot of BU72 at the high energy barrier point of its path ((-0.2, 0.8) in Figure 3). The ligand (BU72) 
is colored in yellow and µOR is depicted in transparent orange. The residues connecting to BU72 at this snapshot is 
shown and labeled. These residues are important residues extracted from tIC1-tIC7 (see Supporting Information).  
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Simulation set up scheme and ligand chemistry 
 
  
 
 
 
 
 
 
 
 
 
 
Figure S.1: a| Snapshot of simulation (water and ions are not shown) including 4 ligands of the same type (here 
BU72), lipid, inactive µOR (PDB: 5C1M) b| Ligands used in the simulations to find the allosteric binding site 
(oxymorphone, BU72, morphine, IBNtxA and carazolol).  
a	
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Figure S.2. tIC1 to tIC5 representing the important amino acids involved in the Bu72 (Lig) 
communication to traverse from allosteric to orthosteric  
 
S.2. Cluster transition path numbers 
Below, are the paths derived from Transition Path Theory (TPT)1 that shows the cluster numbers 
on different possible paths from MSM shows in Figure S.2. The path that we made the ligand 
snapshots is shown in bold (Path8	=	[47	93	48	9	43])	
Path1	=	[61	49	73]	
Path2	=	[61	14	92	23	52	42	43]	
Path3	=	[61	62	14	92	40	57	42	43]	
Path4	=	[61	25	78	28		9	43]	
Path5=	[61	25	49	73]	
Path6	=	[61	93	96		9	43]	
Path7	=	[61	62	40	57	42	34]	
Path8	=	[47	93	48		9	43]	
Path9	=	[47	25	62	92	57	42	21]	
Path10	=	[72	25	14	40	85	65	57	42	43]	
	
Figure S.3. Cluster numbers and the possible paths from allosteric to orthosteric site. The nodes are 
clusters taken from MSM. Edges show the possible paths. 
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Figure S4. a|GLU130-BU72 distance upon binding to hooking site and allosteric sites b| GLY131-BU72 distance 
upon binding to hooking site and allosteric sites. c| GLN212-BU72 distance upon binding to hooking site and allosteric 
sites 
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